Trans Genic Inc. (2342) AI Stock Analysis

• Market Cap: ¥3.51B
• Dividend Yield: 1.84%
• Average Volume (3M): 1.22M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: -0.60%
• EPS Growth: -23595.19%
• Country: JP
• Employees: 236
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -47.97
• Shares Outstanding: 16,999,142
• 10 Day Avg. Volume: 2,603,570
• 30 Day Avg. Volume: 1,215,793
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: ¥198.00 ▼(-4.81%Downside)

The overall stock score for Trans Genic Inc. reflects significant financial challenges, including declining revenue and profitability, as well as negative cash flow. Despite these challenges, the stock's technical indicators show bullish momentum, providing some positive outlook. The concerning valuation, indicated by a negative P/E ratio, further impacts the overall score.

Trans Genic Inc. Business Overview & Revenue Model

Company Description

Trans Genic Inc. (2342) is a biotechnology company specializing in the development and commercialization of innovative genetic products and technologies. The company operates primarily in the agricultural and healthcare sectors, focusing on genetically modified organisms (GMOs) that enhance crop yields and improve resistance to pests and diseases. Additionally, Trans Genic Inc. offers biopharmaceutical solutions, including genetically engineered proteins and antibodies that address various medical conditions. With a strong emphasis on research and development, the company aims to lead advancements in genetic engineering and sustainable practices.

How the Company Makes Money

Trans Genic Inc. generates revenue through multiple streams, primarily from the sale of genetically modified seeds and crops to agricultural producers, which constitute a significant portion of its income. The company also earns revenue from licensing its genetic technologies to other firms in the biotechnology and agricultural sectors. Furthermore, Trans Genic Inc. collaborates with pharmaceutical companies to develop biopharmaceutical products, sharing profits from the sale of these products. Strategic partnerships with research institutions and universities enhance its R&D capabilities, potentially leading to novel products and revenue opportunities. The company may also benefit from government grants and subsidies aimed at promoting agricultural innovation and biotechnology research.

Trans Genic Inc. Financial Statement Overview

Summary

Trans Genic Inc. faces significant financial challenges with declining profitability, negative net profit margins, and increasing leverage. The income statement shows inconsistent revenue growth and operational inefficiencies, while the balance sheet indicates increased financial risk due to higher debt levels. Cash flow issues further highlight the difficulties in sustaining operations.

Income Statement

Trans Genic Inc. has experienced fluctuations in its financial performance over the years. The gross profit margin has decreased from 30.5% in 2022 to 16.7% in 2025, indicating potential pricing pressures or increased cost of sales. The net profit margin has turned negative, with a significant drop from 14.9% in 2022 to -8.4% in 2025, reflecting operational challenges and a decline in profitability. The revenue growth rate has been inconsistent, with a notable decline of 0.6% from 2024 to 2025, suggesting challenges in maintaining sales momentum. The EBIT and EBITDA margins have also turned negative, indicating operational inefficiencies and potential cash flow challenges.

Balance Sheet

The balance sheet reflects a moderate level of stability. The debt-to-equity ratio decreased from 0.28 in 2022 to 0.54 in 2025, indicating increased leverage. The return on equity (ROE) has turned negative, dropping from 28.7% in 2022 to -22.9% in 2025, highlighting profitability challenges. The equity ratio has decreased from 62.6% in 2022 to 49.7% in 2025, indicating a higher proportion of liabilities relative to assets. This suggests potential financial risk if the company cannot control its debt levels or improve profitability.

Cash Flow

Trans Genic Inc.'s cash flow shows some concerning trends. The free cash flow growth rate has been volatile, with a significant negative free cash flow in 2025. The operating cash flow to net income ratio improved in 2025, indicating some efficiency in converting income to cash, but the company's negative net income remains a concern. The free cash flow to net income ratio is negative due to substantial capital expenditures and operating losses, suggesting challenges in generating cash flow to sustain operations.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	13.15B	13.01B	13.08B	11.43B	12.58B	11.05B
Gross Profit	2.29B	2.17B	2.25B	1.99B	3.84B	2.78B
EBITDA	51.34M	-397.56M	240.95M	-119.83M	3.02B	975.06M
Net Income	-248.60M	-1.09B	4.08M	-409.67M	1.88B	546.29M
Balance Sheet
Total Assets	10.45B	9.59B	9.81B	10.67B	10.44B	8.92B
Cash, Cash Equivalents and Short-Term Investments	2.25B	2.56B	2.48B	3.46B	4.62B	3.03B
Total Debt	2.52B	2.58B	2.26B	2.42B	1.82B	2.00B
Total Liabilities	4.80B	4.73B	3.81B	4.55B	3.80B	3.88B
Stockholders Equity	5.56B	4.76B	5.89B	6.02B	6.53B	4.92B
Cash Flow
Free Cash Flow	0.00	-81.35M	-658.12M	-1.74B	1.26B	1.08B
Operating Cash Flow	0.00	94.10M	-392.45M	-1.43B	1.79B	1.22B
Investing Cash Flow	0.00	-287.85M	-280.93M	-216.02M	981.87M	48.43M
Financing Cash Flow	0.00	265.10M	-342.69M	484.98M	-1.18B	10.04M

Trans Genic Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 208.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2342, the sentiment is Positive. The current price of 208 is above the 20-day moving average (MA) of 188.85, above the 50-day MA of 174.88, and above the 200-day MA of 185.75, indicating a bullish trend. The MACD of 10.55 indicates Negative momentum. The RSI at 58.17 is Neutral, neither overbought nor oversold. The STOCH value of 54.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2342.

Trans Genic Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2342	56 Neutral	¥3.51B	―		1.84%	-0.60%	-23595.19%
4594	56 Neutral	¥8.35B	―		―	1473.61%	22.80%
4884	54 Neutral	¥3.42B	―		―	12.66%	24.73%
Sector *	51 Neutral	$7.38B	0.34	-69.01%	2.37%	16.35%	0.39%
4881	38 Underperform	¥4.50B	―		―	1056.04%	21.63%
4591	37 Underperform	¥4.42B	―		―	-96.64%	8.92%
4598	28 Underperform	¥8.19B	―		―	―	-11.46%